| Literature DB >> 25858449 |
Abdissa Edilu, Legesse Adane, Delelegn Woyessa.
Abstract
BACKGROUND: Caylusea absyssinica, a plant used as vegetable and for medicinal purposes was selected for in vitro antibacterial evaluation in this study. The main aim of this study was to isolate compounds from the plant roots and evaluate their antibacterial activities on clinical bacterial test strains.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25858449 PMCID: PMC4379615 DOI: 10.1186/s12941-015-0072-6
Source DB: PubMed Journal: Ann Clin Microbiol Antimicrob ISSN: 1476-0711 Impact factor: 3.944
Inhibition zone (in mm) of the test compounds (compound CA1 and compound CA2) at 50 mg/L and the reference compound (Gentamycin 10 μl)
|
|
|
|
|
|
|
|---|---|---|---|---|---|
| 1 | Compound | 15 | 13 | 13 | 12 |
| 2 | Compound | 12 | 18 | 11 | 13 |
| 3 | DMSO | - | - | - | - |
| 4 | Gentamycin | 20 | 28 | 21 | 23 |
Figure 1General procedures followed in the extraction and isolation of compounds from the roots of
Figure 2The proposed chemical structure compound CA1 (i.e., β-sitosterol).
C-NMR, H-NMR and DEPT-135 data of CA1 in comparison with reported data of β-sitosterol
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|
| 1 | 37.25 | 37.3 | 37.25 | CH2 | ||
| 2 | 31.64 | 31.6 | 31.64 | CH2 | ||
| 3 | 71.82 | 71.8 | 3.54 | 3.53 | 71.83 | CH |
| 4 | 42.28 | 42.2 | 42.28 | CH2 | ||
| 5 | 140.74 | 140.8 | - | C | ||
| 6 | 121.74 | 121.7 | 5.37 | 5.37 | 121.74 | CH |
| 7 | 31.93 | 31.9 | 31.93 | CH2 | ||
| 8 | 31.93 | 31.9 | 31.93 | CH | ||
| 9 | 50.12 | 51.2 | 50.12 | CH | ||
| 10 | 36.51 | 36.5 | - | C | ||
| 11 | 21.08 | 21.1 | 21.08 | CH2 | ||
| 12 | 39.76 | 39.8 | 39.77 | CH2 | ||
| 13 | 42.28 | 42.3 | - | C | ||
| 14 | 56.76 | 56.8 | 56.76 | CH | ||
| 15 | 24.31 | 24.3 | 24.31 | CH2 | ||
| 16 | 28.26 | 28.3 | 28.26 | CH2 | ||
| 17 | 56.04 | 56.0 | 56.05 | CH | ||
| 18 | 11.98 | 11.9 | 0.69 | 0.69 | 11.99 | CH3 |
| 19 | 19.41 | 19.4 | 1.02 | 1.02 | 19.41 | CH3 |
| 20 | 36.51 | 36.2 | 36.56 | CH | ||
| 21 | 18.78 | 18.8 | 0.88 | 0.88 | 18.79 | CH3 |
| 22 | 33.93 | 33.9 | 33.94 | CH2 | ||
| 23 | 26.04 | 26.1 | 26.04 | CH2 | ||
| 24 | 45.82 | 45.9 | 45.82 | CH | ||
| 25 | 29.13 | 29.2 | 29.13 | CH | ||
| 26 | 19.83 | 19.8 | 0.84 | 0.84 | 19.83 | CH3 |
| 27 | 19.41 | 19.3 | 0.86 | 0.86 | 19.41 | CH3 |
| 28 | 23.06 | 23.1 | 23.06 | CH2 | ||
| 29 | 12.27 | 12.2 | 0.82 | 0.81 | 12.20 | CH3 |
Figure 3The chemical structure of compound CA2 (i.e., Stigmasterol).
The observed C-NMR, DEPT-135 and H-NMR data of compound CA2, and the reported C-NMR and H-NMR data of stigmasterol
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|
| 1 | 37.2 | 37.3 | 37.2 | CH2 | ||
| 2 | 31.6 | 31.6 | 31.6 | CH2 | ||
| 3 | 71.8 | 71.8 | 71.8 | 3.44 | 3.45 | CH |
| 4 | 42.2 | 42.3 | 42.3 | CH2 | ||
| 5 | 140.7 | 140.8 | - | C | ||
| 6 | 121.7 | 121.7 | 121.7 | 5.26 | 5.33 | CH |
| 7 | 31.9 | 31.9 | 31.9 | CH2 | ||
| 8 | 31.9 | 31.9 | 31.9 | CH | ||
| 9 | 50.1 | 51.2 | 50.1 | CH | ||
| 10 | 36.5 | 36.5 | - | C | ||
| 11 | 21.0 | 21.1 | 21.0 | CH2 | ||
| 12 | 39.7 | 39.7 | 39.7 | CH2 | ||
| 13 | 42.3 | 42.3 | - | C | ||
| 14 | 56.8 | 57.9 | 56.7 | CH | ||
| 15 | 24.3 | 24.4 | 24.4 | CH2 | ||
| 16 | 28.9 | 28.4 | 28.2 | CH2 | ||
| 17 | 55.9 | 56.1 | 55.9 | CH | ||
| 18 | 12.2 | 11 | 12.2 | 0.61 | 0.68 | CH3 |
| 19 | 19.4 | 21.2 | 19.4 | 0.93 | 1.02 | CH3 |
| 20 | 40.5 | 40.5 | 40.5 | CH | ||
| 21 | 21.1 | 21.2 | 21.1 | 0.76 | 1.01 | CH3 |
| 22 | 138.3 | 138.3 | 138.3 | 5.06 | 5.12 | CH |
| 23 | 129.2 | 129.3 | 129.2 | 4.96 | 4.98 | CH |
| 24 | 51.2 | 51.2 | 51.2 | CH | ||
| 25 | 33.9 | 31.9 | 33.7 | CH | ||
| 26 | 19.0 | 19.0 | 19.0 | 0.72 | 0.86 | CH3 |
| 27 | 21.2 | 21.2 | 21.2 | 0.74 | 0.71 | CH3 |
| 28 | 25.4 | 25.4 | 25.4 | CH2 | ||
| 29 | 12.0 | 12.1 | 11.8 | 0.60 | 0.78 | CH3 |